Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ST6GAL1 | P15907 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800130 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL800834 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL800264 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL800760 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL800358 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL800261 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL13134726 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL16300865 | 0.94 | NT5E (0.49) | NT5EST6GAL1LMNATHRBMTOR | |
| SCHEMBL882301 | 0.92 | NT5E (0.38) | NT5EST6GAL1CYP3A4CYP2C9 | |
| SCHEMBL16300846 | 0.90 | NT5E (0.42) | NT5EST6GAL1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | NT5E 19/4885ST6GAL1 1533/4885LMNA 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.